Plain-English translation of NCT05489549 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking for very early signs of a hereditary heart condition called transthyretin cardiac amyloidosis (or ATTR) in people who carry a specific genetic mutation (V122I). Researchers will use advanced heart imaging and special blood tests to find disease before it causes symptoms, when newer treatments might be most effective.
This genetic mutation is common in Black Americans and can lead to serious heart problems and early death, but many people don't know they carry it. The condition is often found too late for the best treatment options. This study aims to catch it early, when new stabilizing medications may work better to prevent heart failure.
You likely qualify if…
You likely don't qualify if…
You will have detailed heart imaging scans (MRI) to look for early signs of amyloid buildup, and some participants will also undergo exercise MRI to test how your heart responds to activity. You will also provide blood samples for specialized testing. If you are enrolled at UT Southwestern, all testing happens during the same visit; otherwise, visits may be scheduled separately.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States